Gene Editing Manufacturing Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 1.8 billion
Estimated Base Value
2035 Forecast
US$ 7.9 billion
Projected Market Value
CAGR 2026–2035
15.9%
Compound Annual Growth
Largest Segment
Viral Vector Manufacturing
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
North America
Fastest Growing Region
Middle East & Africa
Top Country
United States
By Market Share
Largest market
Key Players
Lonza
Emerging Players
Synthego, MaxCyte
Gene Editing Manufacturing Market Overview
The Gene Editing Manufacturing Market involves the industrial-scale production of components and finished products for therapeutic applications using gene editing technologies in the pharmaceutical sector. This includes the synthesis, purification, and formulation of gene editing tools such as CRISPR-Cas9, TALENs, and ZFNs, along with their delivery systems, which can be viral or non-viral vectors. It also covers ex vivo cell-based products modified through gene editing. The market serves pharmaceutical and biotechnology companies, academic and research institutes, contract development and manufacturing organizations, cell and gene therapy startups, and clinical research organizations, providing the necessary quality, safety, and scalability for clinical development and commercialization.
The Gene Editing Manufacturing Market is estimated at $1.8 Bn in 2025 and is forecast to reach $7.9 Bn in 2035, growing at a CAGR of 15.9% from 2025 to 2035. Demand is driven by the rising prevalence of genetic diseases and increasing R&D investment in gene therapy and editing. A favorable regulatory landscape and technological advancements also contribute to growth. However, high manufacturing costs, complex supply chains, stringent regulatory frameworks, and the challenge of scaling up production are factors that restrain market expansion.
The market is segmented by Type (Viral Vector Manufacturing, Non-Viral Vector Manufacturing, Plasmid DNA Manufacturing, Cell & Gene Editing Therapy Manufacturing, Process Development & Optimization, Analytical Testing & Quality Control, Fill & Finish Services, Cell Line Development & Banking), Technology (CRISPR-Cas Systems, Talens, Zinc Finger Nucleases, Base Editing, Prime Editing, CRISPR-Associated Transposases, Meganucleases), Component & Reagent (Guide Rnas, Cas Nucleases & Effector Proteins, Plasmid DNA, Viral Vectors, Non-Viral Delivery Systems, Cell Culture Media & Supplements, Custom Oligonucleotides, Buffers & Other Biochemical Reagents), Application (Oncology, Monogenic Diseases, Infectious Diseases, Neurological Disorders, Cardiovascular Diseases, Ophthalmological Disorders, Metabolic Disorders, Autoimmune Disorders), End User, and Manufacturing Process. Geographically, the market is served across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Key companies include Lonza, WuXi AppTec, Catalent, FUJIFILM Holdings, CRISPR Therapeutics, Intellia Therapeutics, Charles River Laboratories, BioNTech, Merck KGaA, Sarepta Therapeutics, Vertex Pharmaceuticals, and Oxford Biomedica. The full report provides detailed analysis of these segments, regional insights, and competitive landscape.
Market Definition & Overview
The Gene Editing Manufacturing Market comprises the industrial-scale production of components and finished products for therapeutic applications leveraging gene editing technologies within the pharmaceutical sector. This market specifically covers the synthesis, purification, and formulation of gene editing tools (e.g., CRISPR-Cas9, TALENs, ZFNs), their delivery systems (viral and non-viral vectors), and ex vivo cell-based products modified via gene editing. It encompasses both in-house manufacturing by pharmaceutical and biotech companies and outsourced services provided by Contract Development and Manufacturing Organizations (CDMOs), ensuring the quality, safety, and scalability necessary for clinical development and commercialization of gene-edited therapies.
Scope
- Global geographic coverage across all major pharmaceutical markets.
- Focus on therapeutic applications within the pharmaceutical industry.
- Market analysis covering the period from 2025 to 2035.
Inclusions
- Manufacturing of CRISPR-Cas9, TALENs, and ZFNs components.
- Production of viral vectors for gene editing delivery systems.
- Manufacturing of non-viral gene editing delivery platforms.
- Contract manufacturing services for gene editing-based therapies.
- Cellular therapy manufacturing involving gene editing processes.
- Manufacturing of plasmid DNA for gene editing applications.
Exclusions
- Manufacturing of gene therapies not employing gene editing techniques.
- Research-use-only gene editing reagents and kits.
- Gene editing manufacturing for agricultural or industrial applications.
- Discovery and early-stage research of novel gene editing technologies.
- Diagnostics manufacturing utilizing gene editing techniques.
Market Size Forecast
Executive Summary
• The Gene Editing Manufacturing market is valued at $1.8 Bn in 2025 and is forecast to reach $7.9 Bn by 2035, reflecting a robust CAGR of 15.9% as demand accelerates across every major segment and region over the ten-year outlook.
• Viral Vector Manufacturing leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• Consolidation among specialized CDMOs mastering viral and non-viral delivery systems signals a strategic market shift towards integrated, end-to-end manufacturing solutions essential for scaling gene therapies globally.
• An expanding clinical pipeline across oncology and rare genetic diseases, coupled with accelerating regulatory approvals, critically drives demand for scalable, high-quality, and robust gene editing manufacturing capacity.
• Rapid advancements in base and prime editing technologies necessitate adaptable, future-proof manufacturing platforms, with evolving GMP and CMC regulatory frameworks crucial for ensuring product safety and market entry.
• North America and Europe dominate early-stage manufacturing, but Asia-Pacific is rapidly emerging as a critical production hub, leveraging cost efficiencies and burgeoning biopharma investments to scale global gene therapy supply.
• Significant investment targets automated, closed-system manufacturing technologies to enhance throughput and mitigate contamination risks, concurrently addressing raw material supply vulnerabilities and critical skilled labor shortages.
• The market is poised for transformative growth, driven by an expanding therapeutic scope and the imperative for cost-effective, industrialized production, necessitating a transition towards sophisticated, integrated manufacturing platforms globally.
Key Market Takeaways
Critical findings and data points from this market research study.
Market Base Valuation
The Gene Editing Manufacturing Market stood at $1.8 billion in the base year, establishing a significant starting point for its rapid expansion.
Forecasted Market Reach
By the forecast year, the market is expected to surge to $7.9 billion, driven by increasing adoption and therapeutic breakthroughs in gene therapy.
Strong Growth Momentum
The market's remarkable growth is evidenced by a Compound Annual Growth Rate (CAGR) of 15.9% between the base and forecast years, indicating sustained demand.
Regional Leadership
North America is anticipated to maintain its leadership in the market, propelled by substantial R&D investments and a well-established biotechnology infrastructure.
Segment Dominance
The viral vector manufacturing segment is expected to hold a significant market share, remaining crucial for efficient gene delivery in therapeutic applications.
Process Optimization Trend
A notable trend in gene editing manufacturing involves significant investment in automation and process optimization to enhance scalability, efficiency, and cost-effectiveness.
Market Dynamics
Market Trends
- Increased adoption of CRISPR-Cas9 for therapeutic applications.
- Shift towards automated and high-throughput manufacturing processes.
- Growing focus on ex vivo gene editing technologies.
- Development of improved in vivo delivery systems.
Growth Drivers
- Rising prevalence of genetic diseases globally.
- Increasing R&D investment in gene therapy and editing.
- Favorable regulatory landscape and fast-track approvals.
- Technological advancements improving gene editing efficacy.
Restraints
- High manufacturing costs and complex supply chains limit market accessibility.
- Stringent and evolving regulatory frameworks pose significant approval hurdles.
- Scaling up production to meet demand remains a significant technical challenge.
- Shortage of specialized expertise hinders efficient process development and optimization.
Opportunities
- Developing novel gene editing technologies beyond CRISPR.
- Expanding applications into non-oncology and rare diseases.
- Geographic expansion into high-growth emerging markets.
- Strategic partnerships for advanced manufacturing scale.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Viral Vector ManufacturingNon-Viral Vector ManufacturingPlasmid DNA ManufacturingCell & Gene Editing Therapy ManufacturingProcess Development & OptimizationAnalytical Testing & Quality ControlFill & Finish ServicesCell Line Development & Banking |
| By Technology | CRISPR-Cas SystemsTalensZinc Finger NucleasesBase EditingPrime EditingCRISPR-Associated TransposasesMeganucleases |
| By Component & Reagent | Guide RnasCas Nucleases & Effector ProteinsPlasmid DNAViral VectorsNon-Viral Delivery SystemsCell Culture Media & SupplementsCustom OligonucleotidesBuffers & Other Biochemical Reagents |
| By Application | OncologyMonogenic DiseasesInfectious DiseasesNeurological DisordersCardiovascular DiseasesOphthalmological DisordersMetabolic DisordersAutoimmune Disorders |
| By End User | Pharmaceutical & Biopharmaceutical CompaniesBiotechnology CompaniesAcademic & Research InstitutesContract Development & Manufacturing OrganizationsCell and Gene Therapy StartupsClinical Research Organizations |
| By Manufacturing Process | Cell Line & Plasmid DevelopmentVector ProductionVector Purification & ConcentrationFormulation & Fill & FinishQuality Control & AnalyticsProcess Development & OptimizationStorage & LogisticsRegulatory Affairs Support |
Regional Analysis
- North America leads the gene editing manufacturing market due to its robust pharmaceutical industry, significant R&D investments, and numerous biotechnology companies. The presence of major academic institutions and a strong regulatory framework further propels its dominance in gene therapy innovation and production.
- Asia-Pacific is the fastest-growing gene editing manufacturing market, propelled by escalating healthcare spending, increasing patient pools, and supportive government initiatives for biotechnology. Countries like China and Japan are heavily investing in research infrastructure and local manufacturing capabilities, driving rapid expansion.
- A noteworthy trend is the strategic expansion of localized gene editing manufacturing hubs across Europe and North America. This aims to enhance supply chain resilience, reduce logistics costs, and improve access to advanced therapies, fostering regional specialization and quicker patient access.
| North AmericaXX.X% | EuropeXX.X% | Asia PacificXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Dominates the gene editing manufacturing market due to extensive R&D investments, advanced biotech infrastructure, and strong regulatory support from bodies like the FDA.
- The presence of leading pharmaceutical and biotech companies drives innovation and production capacity.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Represents a developing market for gene editing manufacturing, characterized by nascent clinical trial activities and growing interest in biotechnological advancements.
- Investments are gradually increasing, though infrastructure and regulatory frameworks are still maturing.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- A significant player with robust research institutions, established pharmaceutical companies, and supportive regulatory frameworks from the EMA.
- Countries like the UK, Germany, and Switzerland are key hubs for gene therapy development and manufacturing.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Experiences rapid growth, fueled by increasing government funding, expanding research capabilities, and a large patient base, particularly in countries like China, Japan, and South Korea.
- This region is becoming a critical manufacturing hub with strong investment in biotech.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Currently holds a smaller share but is poised for strategic growth, driven by increasing healthcare expenditure, government initiatives to diversify economies, and emerging biotech investments in select countries.
- Collaborative partnerships are key to its development.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | The United States leads in gene editing manufacturing due to extensive R&D investments, a robust biotech ecosystem, and a significant number of ongoing clinical trials for gene therapies. Its advanced infrastructure and substantial funding propel the development and production of novel gene-edited products. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | Brazil represents the largest gene therapy market in South America, with increasing government and private investments in biomedical research and manufacturing infrastructure. Its large population and growing demand for advanced therapies drive the potential for gene editing manufacturing. |
| 3 | Germany | US$ XX.X Mn | XX.X% | Germany is a powerhouse in pharmaceutical manufacturing and advanced biotech, boasting a strong regulatory framework and significant public and private investments in gene therapy R&D and production. Its well-established contract development and manufacturing organizations (CDMOs) are crucial for gene editing products. |
| 4 | China | US$ XX.X Mn | XX.X% | China is experiencing rapid growth in gene editing manufacturing, driven by massive government investment, a large patient population, and a strong focus on biotech innovation and domestic production. Its rapidly expanding CDMO capabilities and clinical trial landscape make it a dominant force. |
| 5 | United Arab Emirates | US$ XX.X Mn | XX.X% | The UAE is rapidly investing in healthcare infrastructure and establishing itself as a regional hub for advanced medical technologies, including gene therapy. Its strategic vision and economic diversification efforts are driving the development of local gene editing manufacturing capabilities. |
Countries Covered (27)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Switzerland, Italy, Spain, Russia, Rest of Europe, China, Japan, South Korea, India, Australia, Taiwan, Singapore, Malaysia, Rest of Asia Pacific, United Arab Emirates, Saudi Arabia, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Lonza | XX.X% | Leverage an extensive global manufacturing network and expertise to be a leading CDMO partner for complex cell and gene therapies. | — | — | Cell & Gene TechnologiesBiologics ManufacturingSmall Molecules+1 |
| 2 | WuXi AppTec | XX.X% | Offer integrated end-to-end R&D and manufacturing services globally, especially for biopharmaceuticals and cell & gene therapies. | — | — | CDMO ServicesResearch ServicesCell & Gene Therapy CTDMO+1 |
| 3 | Catalent | XX.X% | Provide advanced delivery technologies and integrated development and manufacturing solutions for biopharmaceuticals and cell & gene therapies. | — | — | Biologics Drug SubstanceOral Dose DeliveryCell & Gene Therapy+1 |
| 4 | FUJIFILM Holdings | XX.X% | Leverage advanced materials science and manufacturing expertise to become a leading CDMO, particularly in biologics and advanced therapies through FUJIFILM Diosynth Biotechnologies. | — | — | FUJIFILM Diosynth Biotechnologies CDMOImaging SolutionsHealthcare Solutions+1 |
| 5 | CRISPR Therapeutics | XX.X% | Develop transformative gene-edited medicines using its proprietary CRISPR/Cas9 platform for a wide range of diseases. | — | — | Exa-celCTX110CTX310+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Lonza, WuXi AppTec, Catalent, FUJIFILM Holdings, CRISPR Therapeutics, Intellia Therapeutics, Charles River Laboratories, BioNTech, Merck KGaA, Sarepta Therapeutics, Vertex Pharmaceuticals, Oxford Biomedica, AGC Inc., Editas Medicine, Beam Therapeutics, Precision Biosciences, Poseida Therapeutics, GenScript Biotech, Cellectis, Verve Therapeutics
The global Gene Editing Manufacturing market features a competitive landscape led by Lonza, WuXi AppTec, Catalent, FUJIFILM Holdings, CRISPR Therapeutics, and Intellia Therapeutics, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
Lonza
WuXi AppTec
Catalent
FUJIFILM Holdings
CRISPR Therapeutics
Intellia Therapeutics
Charles River Laboratories
BioNTech
Merck KGaA
Sarepta Therapeutics
Vertex Pharmaceuticals
Oxford Biomedica
AGC Inc.
Editas Medicine
Beam Therapeutics
Precision Biosciences
Poseida Therapeutics
GenScript Biotech
Cellectis
Verve Therapeutics
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Lonza Expands Viral Vector Manufacturing for Gene Editing Therapies
Leading CDMO Lonza announced the substantial completion of its new state-of-the-art facility, specifically designed to boost viral vector manufacturing capacity for advanced gene editing therapies. This strategic expansion aims to meet the escalating global demand for clinical and commercial supply of gene therapy vectors.
Thermo Fisher Scientific Launches Automated Gene Editing Workflow Solution
Thermo Fisher Scientific unveiled a new integrated and automated platform engineered to streamline the entire gene editing workflow, from guide RNA synthesis to cell processing. The system promises enhanced efficiency, reproducibility, and scalability for both research and GMP-compliant manufacturing applications.
CRISPR Therapeutics Partners with AGC Biologics for Ex Vivo Gene Editing Program
CRISPR Therapeutics announced a strategic manufacturing partnership with AGC Biologics to scale up production of its lead ex vivo gene editing therapy candidate. This collaboration will leverage AGC Biologics' expertise to optimize processes and secure robust supply for ongoing clinical trials and future commercialization.
Precision BioSciences Secures US$ XX.X Investment for Allogeneic Gene Editing Manufacturing
Precision BioSciences, a pioneer in allogeneic gene-edited cell therapies, successfully closed a US$ XX.X Series C funding round, primarily earmarked for advancing its proprietary manufacturing capabilities. The investment will accelerate the development and scale-up of its off-the-shelf gene editing product pipeline and technology platforms.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $1.8 Bn |
| Market Size (Forecast) | $7.9 Bn |
| CAGR | 15.9% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 27 Countries |
| Segments Covered | 6 Segments, 45 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the Gene Editing Manufacturing Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The Gene Editing Manufacturing market is estimated at $1.8 Bn in 2025. It is forecast to reach $7.9 Bn by 2035, indicating substantial growth over the decade.
The Gene Editing Manufacturing market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 15.9% from 2025 to 2035. This growth is driven by increasing demand for gene-edited therapies.
The market is segmented by Type (e.g., Viral Vector Manufacturing, Plasmid DNA Manufacturing), Technology (e.g., CRISPR-Cas Systems, Talens), Component & Reagent (e.g., Guide Rnas, Plasmid DNA), Application (e.g., Oncology, Monogenic Diseases), End User, and Manufacturing Process.
Leading companies in this market include Lonza, WuXi AppTec, Catalent, FUJIFILM Holdings, CRISPR Therapeutics, Intellia Therapeutics, Charles River Laboratories, BioNTech, Merck KGaA, Sarepta Therapeutics, Vertex Pharmaceuticals, and Oxford Biomedica.
The report covers market size and growth forecasts, detailed segmentation by type, technology, component, application, end user, and manufacturing process. It also includes regional analysis and profiles of leading companies in the Gene Editing Manufacturing market.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
Digital Gene Manufacturing Market
$536.1 Mn in 2025 · 19.6% CAGR
Gene Editing Market
$5.2 Bn in 2025 · 15.2% CAGR
Gene Manufacturing Market
$6.4 Bn in 2025 · 15.4% CAGR
Gene Therapy Manufacturing Platform Market
$4.8 Bn in 2025 · 17.6% CAGR
Cell Manufacturing Market
$7.8 Bn in 2025 · 14.7% CAGR
Digital Cell Manufacturing Market
$918.0 Mn in 2025 · 18.7% CAGR
Digital Therapeutic Manufacturing Market
$284.0 Mn in 2025 · 18.9% CAGR
Life Science Manufacturing Intelligence Market
$1.1 Bn in 2025 · 13.5% CAGR